• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在基层医疗服务中使用便携式设备PICO-6和COPD-6进行慢性阻塞性肺疾病(COPD)检测时,避免假阴性的第一秒用力呼气容积(FEV1)/用力呼气6秒容积(FEV6)截断点

FEV1/FEV6 Cutoff Points to Avoid False Negatives When Using Portable Devices, PICO-6 and COPD-6, in COPD Detection in Primary Healthcare Services.

作者信息

Hernandez-Mezquita Miguel A, Santos-Ventura Idania De Los, Hidalgo-Sierra Vanesa, Pérez-Trullen Alfonso, Garcia Ruth García, Clavero-Sánchez Tamara, Barrueco-Otero Enrique

机构信息

Pneumology Department, Salamanca University Hospital, 37007 Salamanca, Spain.

Department of Medicine, University of Salamanca (USAL), 37007 Salamanca, Spain.

出版信息

J Clin Med. 2025 Jan 17;14(2):576. doi: 10.3390/jcm14020576.

DOI:10.3390/jcm14020576
PMID:39860580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11765564/
Abstract

: Chronic obstructive pulmonary disease (COPD) is a frequent but underdiagnosed disease, primarily due to the lack of access to forced spirometry (FS) in primary care. Portable, easy-to-use expiratory flow meters like Piko-6 and COPD-6 that measure FEV, FEV, and FEV/FEV ratio provide an alternative. Given that Piko-6 and COPD-6 devices measure FEV but not FVC, the aim of the study is to determine the optimal cutoff value for the FEV/FEV ratio of each device to avoid false negatives when these devices are used for COPD screening in primary care (PC). : A total of 664 patients of 35 years of age or older with a cumulative tobacco consumption of 10 or more packs/year were recruited at two university hospitals. FS (gold standard) was performed and FEV, FVC, and FEV/FVC measurements were compared with FEV, FEV, and FEV/FEV measurements acquired using Piko-6 and COPD-6 devices. The devices were compared using statistical methods including Pearson correlation coefficients, the Youden index (YI), kappa coefficient, Bland-Altman plots, and ROC curves analysis. : Correlations between FEV/FEV using Piko-6 and COPD-6 and FEV/FVC with FS were 0.79 and 0.73, respectively. Piko-6 achieved the best YI in FEV/FEV (0.73), whereas for COPD-6, it was 0.80. Concordance between Piko-6 and FS was 83.9% (kappa 0.67 ± 0.028) and for COPD-6, it was 68.7% (kappa 0.42 ± 0.02). : This is the first study that compares two hand-held expiratory flow meters with FS. Piko-6 and COPD-6 devices are effective tools for COPD detection, as their measurements provide a good correlation with FS. In order to avoid false negative results, the FEV/FEV cutoff point needs to be increased to 0.73 and 0.80 with Piko-6 and COPD-6, respectively.

摘要

慢性阻塞性肺疾病(COPD)是一种常见但诊断不足的疾病,主要原因是基层医疗中无法进行肺功能仪测定(FS)。像Piko - 6和COPD - 6这样的便携式、易于使用的呼气流量计可以测量第一秒用力呼气容积(FEV₁)、用力肺活量(FVC)和FEV₁/FVC比值,提供了一种替代方法。鉴于Piko - 6和COPD - 6设备测量FEV₁但不测量FVC,本研究的目的是确定每种设备的FEV₁/FEV₁比值的最佳截断值,以避免在基层医疗(PC)中使用这些设备进行COPD筛查时出现假阴性。

在两家大学医院共招募了664名年龄在35岁及以上、累积吸烟量为每年10包或更多的患者。进行了肺功能仪测定(金标准),并将FEV₁、FVC和FEV₁/FVC测量值与使用Piko - 6和COPD - 6设备获得的FEV₁、FEV₁和FEV₁/FEV₁测量值进行比较。使用包括Pearson相关系数、约登指数(YI)、kappa系数、Bland - Altman图和ROC曲线分析在内的统计方法对这些设备进行比较。

使用Piko - 6和COPD - 6时FEV₁/FEV₁与使用肺功能仪测定时的FEV₁/FVC之间的相关性分别为0.79和0.73。Piko - 6在FEV₁/FEV₁方面获得了最佳约登指数(0.73),而COPD - 6的约登指数为0.8。Piko - 6与肺功能仪测定的一致性为83.9%(kappa 0.67±0.028),COPD - 6与肺功能仪测定的一致性为68.7%(kappa 0.42±0.02)。

这是第一项将两种手持式呼气流量计与肺功能仪测定进行比较的研究。Piko - 6和COPD - 6设备是检测COPD的有效工具,因为它们的测量值与肺功能仪测定有良好的相关性。为了避免假阴性结果,使用Piko - 6和COPD - 6时,FEV₁/FEV₁的截断点分别需要提高到0.73和0.80。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/93a6914ad368/jcm-14-00576-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/f4e488e19d32/jcm-14-00576-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/e061086ac236/jcm-14-00576-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/218381b53ef1/jcm-14-00576-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/93a6914ad368/jcm-14-00576-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/f4e488e19d32/jcm-14-00576-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/e061086ac236/jcm-14-00576-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/218381b53ef1/jcm-14-00576-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0550/11765564/93a6914ad368/jcm-14-00576-g004.jpg

相似文献

1
FEV1/FEV6 Cutoff Points to Avoid False Negatives When Using Portable Devices, PICO-6 and COPD-6, in COPD Detection in Primary Healthcare Services.在基层医疗服务中使用便携式设备PICO-6和COPD-6进行慢性阻塞性肺疾病(COPD)检测时,避免假阴性的第一秒用力呼气容积(FEV1)/用力呼气6秒容积(FEV6)截断点
J Clin Med. 2025 Jan 17;14(2):576. doi: 10.3390/jcm14020576.
2
Usefulness of The Piko-6 Portable Device for Early COPD Detection in Primary Care.Piko-6便携式设备在基层医疗中早期检测慢性阻塞性肺疾病的效用。
Arch Bronconeumol (Engl Ed). 2018 Sep;54(9):460-466. doi: 10.1016/j.arbres.2018.04.015. Epub 2018 Jun 5.
3
PIKO-6® vs. forced spirometry in asthmatic children.PIKO-6®与哮喘儿童用力肺活量测定法的比较
Pediatr Pulmonol. 2014 Dec;49(12):1170-6. doi: 10.1002/ppul.22996. Epub 2014 Feb 5.
4
FEV1/FEV6 in Primary Care Is a Reliable and Easy Method for the Diagnosis of COPD.基层医疗中使用第1秒用力呼气容积/用力呼气6秒容积是诊断慢性阻塞性肺疾病的可靠且简便的方法。
Respir Care. 2016 Mar;61(3):349-53. doi: 10.4187/respcare.04348. Epub 2015 Nov 3.
5
Simplified COPD screening: validation of the PiKo-6® in primary care.简化慢性阻塞性肺疾病筛查:PiKo-6®在初级保健中的验证
Prim Care Respir J. 2011 Jun;20(2):190-8, 2 p following 198. doi: 10.4104/pcrj.2011.00040.
6
FEV1/FEV6 is effective as a surrogate for FEV1/FVC in the diagnosis of chronic obstructive pulmonary disease.FEV1/FEV6 可作为 FEV1/FVC 的替代指标,用于诊断慢性阻塞性肺疾病。
Indian J Tuberc. 2021 Apr;68(2):230-235. doi: 10.1016/j.ijtb.2020.09.002. Epub 2020 Sep 6.
7
Validity of the Handheld Expiratory Flowmeter for COPD Screening in the Primary Care Setting of China.手持式呼气峰流速仪在中国基层医疗环境下用于 COPD 筛查的有效性。
Int J Chron Obstruct Pulmon Dis. 2021 Jul 8;16:2039-2047. doi: 10.2147/COPD.S312190. eCollection 2021.
8
Comparison between FEV/FEV and FEV/FVC as screening of chronic obstructive pulmonary disease.以FEV/FEV与FEV/FVC作为慢性阻塞性肺疾病筛查指标的比较。
Med J Malaysia. 2017 Oct;72(5):286-290.
9
Determination of the efficacy of FEV6 as a surrogate for FVC in the diagnostic screening for chronic obstructive pulmonary disease through the comparison of FEV1/FVC and FEV1/FEV6 ratios.通过比较FEV1/FVC和FEV1/FEV6比值,确定FEV6作为慢性阻塞性肺疾病诊断筛查中FVC替代指标的有效性。
J Bras Pneumol. 2007 Mar-Apr;33(2):148-51. doi: 10.1590/s1806-37132007000200008.
10
Cut-off value of FEV1/FEV6 to determine airflow limitation using handheld spirometry in subjects with risk of chronic obstructive pulmonary disease.使用手持式肺活量计测定慢性阻塞性肺疾病高危人群的 FEV1/FEV6 比值来确定气流受限的截断值。
Korean J Intern Med. 2021 May;36(3):629-635. doi: 10.3904/kjim.2019.314. Epub 2020 Jun 24.

本文引用的文献

1
Accuracy of PIKO-6® and COPD-6® Devices in COPD Screening.PIKO-6®和COPD-6®设备在慢性阻塞性肺疾病(COPD)筛查中的准确性。
Arch Bronconeumol. 2025 Feb;61(2):110-112. doi: 10.1016/j.arbres.2024.10.002. Epub 2024 Oct 22.
2
Comparing performance of primary care clinicians in the interpretation of SPIROmetry with or without Artificial Intelligence Decision support software (SPIRO-AID): a protocol for a randomised controlled trial.比较使用或不使用人工智能决策支持软件(SPIRO-AID)对 SPIROmetry 进行解读的初级保健临床医生的表现:一项随机对照试验方案。
BMJ Open. 2024 Jul 1;14(6):e086736. doi: 10.1136/bmjopen-2024-086736.
3
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.
全球慢性阻塞性肺疾病倡议 2023 年报告:GOLD 执行摘要。
Eur Respir J. 2023 Apr 1;61(4). doi: 10.1183/13993003.00239-2023. Print 2023 Apr.
4
Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trials.基于人工智能的软件有助于哮喘和慢性阻塞性肺疾病临床试验中的肺活量测定质量控制。
ERJ Open Res. 2023 Jan 3;9(1). doi: 10.1183/23120541.00292-2022. eCollection 2023 Jan.
5
Beyond Access: Factors Associated With Spirometry Underutilization Among Patients With a Diagnosis of COPD in Urban Tertiary Care Centers.超越获取途径:城市三级医疗中心慢性阻塞性肺疾病患者肺功能检查未充分利用的相关因素
Chronic Obstr Pulm Dis. 2022 Oct 26;9(4):538-548. doi: 10.15326/jcopdf.2022.0303.
6
Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年慢性阻塞性肺疾病负担及其可归因危险因素:2019 年全球疾病负担研究结果。
BMJ. 2022 Jul 27;378:e069679. doi: 10.1136/bmj-2021-069679.
7
Accuracy of portable spirometers in the diagnosis of chronic obstructive pulmonary disease A meta-analysis.便携式肺量计诊断慢性阻塞性肺疾病的准确性:一项荟萃分析。
NPJ Prim Care Respir Med. 2022 Apr 19;32(1):15. doi: 10.1038/s41533-022-00275-x.
8
Development and validation of a prediction index for recent mortality in advanced COPD patients.慢性阻塞性肺疾病(COPD)晚期患者近期死亡率预测指标的建立与验证。
NPJ Prim Care Respir Med. 2022 Jan 13;32(1):2. doi: 10.1038/s41533-021-00263-7.
9
Performance and Clinical Utility of Various Chronic Obstructive Pulmonary Disease Case-Finding Tools.各种慢性阻塞性肺疾病筛查工具的性能和临床实用性。
Int J Chron Obstruct Pulmon Dis. 2021 Dec 18;16:3405-3415. doi: 10.2147/COPD.S339340. eCollection 2021.
10
Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.在 SPIROMICS 队列中分析:用力呼气量/用力肺活量比值对发展为 COPD 风险的吸烟者早期气道疾病的识别意义。
Chest. 2022 Apr;161(4):949-959. doi: 10.1016/j.chest.2021.10.046. Epub 2021 Nov 10.